Affiliations: Department of Pneumology & Allergy, Medical
University of Lodz, Lodz, Poland
Note: [] Corresponding author: Maciej Ciebiada, Department of Pneumology
and Allergy, Medical University of Lodz,
Kopcińskiego Street 22, 90-153 Lodz, Poland. Tel.:
+48 42 678 7505; Fax: +48 42 678 2129; E-mail: maciej_ciebiada@op.pl
Abstract: Although eicosanoids are involved in lung carcinogenesis they were
poorly investigated in exhaled breath condensate (EBC) and bronchoalveolar
lavage fluid (BALf) in patients with primary lung cancer. In this study 17
patients with diagnosed non-small cell lung cancer, 10 healthy smokers and 12
healthy nonsmokers were included. The levels of cys-LTs, 8-isoprostane, LTB4
and PGE2 were measured before any treatment in the EBC of all patients and in
BALf of patients with lung cancer by enzyme linked immunosorbent assay.
8-isoprostane, LTB4, cys-LTs and PGE2 were detectable in the EBC and BALf.
There were no significant differences between healthy smokers and nonsmokers in
concentrations of all measured mediators. Compared with both healthy controls,
patients with diagnosed lung cancer displayed higher concentrations of cys-LTs
(p< 0.05) and LTB4 (p < 0.05) in EBC. In patients with lung cancer, the
mean concentrations of all measured mediators were significantly higher in BALf
compared with EBC and there was a significant, positive correlation between
concentration of cys-LTs, LTB_{4} and 8-isoprostane in BALf
and their concentrations in the EBC (r=0.64, p < 0.05, r=0.59, p< 0.05,
r=0.53, p< 0.05 respectively). Since cys-LT, LTB4 and 8-isoprostane
concentrations in EBC from patients with lung cancer reflect their
concentrations in BALf, they may serve as a possible non-invasive method to
monitor the disease and to assess the effectiveness of therapy.
